CA
NZ
UK
AU
IND
US
Setting ambitious long-term targets is usually meant to reassure investors, but for a NASDAQ-listed digital health company today, it appears to have done the opposite. Omada Health (NASDAQ:OMDA) is sliding sharply following its inaugural Investor Day, where management unveiled targets of at least 20% …
It's rare for one piece of research to move a stock this much, but that's what's happening with Korsana Biosciences (NASDAQ:KRSA) today after UBS initiated coverage with a Buy rating and a $55 price target, implying substantial upside from current levels for a name …
Getting a drug candidate into its actual target population for the first time is a distinct milestone from any dosing that came before it, and that's what happened today for Clearmind Medicine (NASDAQ:CMND). Every prior round of testing for CMND-100 involved healthy participants without …
There's a particular kind of signal that comes from an executive putting personal money into a stock that's down more than half for the year, and that's exactly what's driving Alphatec Holdings (NASDAQ:ATEC) higher today. A regulatory filing revealed that CEO Patrick Miles purchased …
Silexion Therapeutics Corp. (NASDAQ: SLXN) shares closed up 21% at $0.42 after announcing its attendance at upcoming September 2026 industry events, whereLeadershipwill highlight oncology progress and the pan-KRAS RNAi candidate SIL204 in pancreatic cancer.
Tenon Medical, Inc. (NASDAQ: TNON) shares closed up 117% at $5.30 on news that the company fully repaid about $5.16 million of senior convertible notes ahead of maturity.
AEON Biopharma, Inc. (NYSE: AEON) shares closed up 26% at $0.29 after the company reported pilot forced-degradation data showing ABP-450 had comparable thermal potency-loss and oxidative-stress patterns to BOTOX.
CDT Equity (NASDAQ: CDT) shares fell 43% to $0.34 following an update noting minority-owned Sarborg's use of patented Signature Intelligence and quantum models in neuropsychiatric drug discovery, covering depression, bipolar disorder, anxiety, and schizophrenia.
Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares closed up 23% at $2.56 following its second-quarter 2026 update, which emphasized enhanced capital reserves via a $12.0 million private placement.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares fell 17% to $0.33 after the company announced it will implement a 1-for-20 reverse share split, with post-split Nasdaq trading expected to begin September 14, 2026.
Please wait processing your request...